Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is primarily used to treat major depressive disorder (MDD) in adults and adolescents aged 12 years and older, as well as generalized anxiety disorder (GAD) in adults. Escitalopram works by increasing levels of serotonin in the brain through potent inhibition of the serotonin transporter (SERT), which prevents reuptake of serotonin into presynaptic neurons. This action helps restore serotonergic function, alleviating symptoms of depression and anxiety. Escitalopram exhibits high selectivity for SERT compared to other monoamine transporters, contributing to its favorable side effect profile relative to less-selective SSRIs. Additionally, it binds allosterically to SERT, potentially enhancing its efficacy and speed of onset compared with other SSRIs. The drug was originally developed by Lundbeck.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram.